Tyrosine kinase inhibitor combination

This page covers all Tyrosine kinase inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BCR-ABL, SRC family kinases, EGFR and MET.

Targets

BCR-ABL, SRC family kinases · EGFR and MET

Marketed (1)

• DW6012(Dasidiem tab. 10/100mg) · Dong Wha Pharmaceutical Co. Ltd. · Oncology
  DW6012 is a fixed-dose combination of dasatinib and another agent that inhibits tyrosine kinases to suppress abnormal cell proliferation.

Phase 3 pipeline (1)

• Savolitinib + Osimertinib · Hutchison Medipharma Limited · Oncology
  Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer.